IP Library › Granted Patent US 11,732,000
Granted Patent B2
US 11,732,000 · App. 17/396,034 · Granted Aug 22, 2023

Oxysterols and methods of use thereof

Inventors: Francesco G. Salituro (Marlborough, MA); Albert Jean Robichaud (Boston, MA); Gabriel Martinez Botella (Wayland, MA); Boyd L. Harrison (Princeton Junction, NJ)
Assignee: Sage Therapeutics, Inc.
C07J9/00A61P3/00A61P23/00A61P25/20C07J17/00C07J7/002C07J9/005C07J13/005C07J13/007C07J31/006C07J41/0061
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,732,000
App. No.
17/396,034
Granted
Aug 22, 2023
Kind
B2
Abstract

Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R 1 , R 2 , and R 3 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

Claims (12)

1. A compound selected from the group consisting of:

2. A pharmaceutically acceptable salt of a compound selected from the group consisting of:

3. The compound of claim 1 , wherein the compound is:

4. The pharmaceutically acceptable salt of a compound of claim 2 , wherein the compound is:

5. The compound of claim 1 , wherein the compound is:

6. The pharmaceutically acceptable salt of a compound of claim 2 , wherein the compound is:

7. The compound of claim 1 , wherein the compound is:

8. The pharmaceutically acceptable salt of a compound of claim 2 , wherein the compound is:

9. The compound of claim 1 , wherein the compound is:

10. The pharmaceutically acceptable salt of a compound of claim 2 , wherein the compound is:

11. A pharmaceutical composition comprising a pharmaceutically acceptable salt of a compound of any one of claim 2 , 4 , 6 , 8 or 10 and a pharmaceutically acceptable carrier.

12. A pharmaceutical composition comprising a compound of any one of claim 1 , 3 , 5 , 7 , or 9 and a pharmaceutically acceptable carrier.

Assignments (3)
CHANGE OF NAME Recorded Mar 17, 2026
From: SAGE THERAPEUTICS, INC.
To: SAGE THERAPEUTICS, LLC
Reel/Frame 075169/0407 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2025
From: SALITURO, FRANCESCO G.; ROBICHAUD, ALBERT JEAN; BOTELLA, GABRIEL MARTINEZ
To: SAGE THERAPEUTICS, INC.
Reel/Frame 071340/0170 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2025
From: BOTELLA, GABRIEL MARTINEZ; HARRISON, BOYD L.; ROBICHAUD, ALBERT JEAN; SALITURO, FRANCESCO G.
To: SAGE THERAPEUTICS, INC.
Reel/Frame 071510/0754 →
Continuity (4)
Continuation 15742424
Provisional Application 62332931 · May 6, 2016
Provisional Application 62189068 · Jul 6, 2015
Related Publication 20220048943A1 · Feb 17, 2022
Cited By (3)
US 12,331,070 US 12,448,409 US 12,540,157